Smith Asset Management Group LP decreased its position in shares of Prothena Corporation PLC (NASDAQ:PRTA) by 4.3% during the second quarter, Holdings Channel reports. The institutional investor owned 6,740 shares of the biotechnology company’s stock after selling 300 shares during the period. Smith Asset Management Group LP’s holdings in Prothena Corporation PLC were worth $365,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of PRTA. Crescent Grove Advisors LLC purchased a new position in shares of Prothena Corporation PLC during the second quarter worth about $271,000. Schwab Charles Investment Management Inc. boosted its position in shares of Prothena Corporation PLC by 6.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 163,681 shares of the biotechnology company’s stock worth $8,859,000 after buying an additional 9,824 shares in the last quarter. Sei Investments Co. purchased a new position in shares of Prothena Corporation PLC during the second quarter worth about $176,000. Russell Investments Group Ltd. boosted its position in shares of Prothena Corporation PLC by 181.6% in the second quarter. Russell Investments Group Ltd. now owns 33,876 shares of the biotechnology company’s stock worth $1,834,000 after buying an additional 21,846 shares in the last quarter. Finally, Barometer Capital Management Inc. purchased a new position in shares of Prothena Corporation PLC during the second quarter worth about $373,000.

Prothena Corporation PLC (NASDAQ PRTA) opened at 58.38 on Tuesday. Prothena Corporation PLC has a 12-month low of $40.58 and a 12-month high of $69.53. The stock has a 50 day moving average of $60.51 and a 200 day moving average of $55.07. The firm’s market cap is $2.23 billion.

Prothena Corporation PLC (NASDAQ:PRTA) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.43. Prothena Corporation PLC had a negative net margin of 527.56% and a negative return on equity of 33.20%. The firm had revenue of $26.81 million during the quarter, compared to analyst estimates of $16.08 million. During the same quarter last year, the business earned ($1.18) EPS. The company’s revenue was up 7951.1% compared to the same quarter last year. On average, equities research analysts anticipate that Prothena Corporation PLC will post ($4.54) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.watchlistnews.com/smith-asset-management-group-lp-has-365000-position-in-prothena-corporation-plc-prta/1489586.html.

A number of research analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Prothena Corporation PLC from a “hold” rating to a “buy” rating and set a $66.00 price objective for the company in a report on Friday. BidaskClub cut shares of Prothena Corporation PLC from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Jefferies Group LLC assumed coverage on shares of Prothena Corporation PLC in a report on Monday, July 10th. They set a “buy” rating and a $100.00 price objective for the company. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $70.00 price objective on shares of Prothena Corporation PLC in a report on Thursday, July 6th. Finally, ValuEngine upgraded shares of Prothena Corporation PLC from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $77.09.

In other Prothena Corporation PLC news, insider Karin L. Walker sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $64.89, for a total transaction of $324,450.00. Following the completion of the transaction, the insider now owns 5,000 shares in the company, valued at approximately $324,450. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Dennis J. Selkoe sold 3,500 shares of the firm’s stock in a transaction that occurred on Friday, July 7th. The stock was sold at an average price of $58.11, for a total transaction of $203,385.00. Following the transaction, the director now owns 6,345 shares of the company’s stock, valued at approximately $368,707.95. The disclosure for this sale can be found here. 3.10% of the stock is currently owned by company insiders.

Prothena Corporation PLC Company Profile

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Want to see what other hedge funds are holding PRTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prothena Corporation PLC (NASDAQ:PRTA).

Institutional Ownership by Quarter for Prothena Corporation PLC (NASDAQ:PRTA)

Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.